Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Juniper Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results Signs Agreement to be Acquired by Catalent, Inc. CRINONE® Revenues Increased 12% and Juniper Pharma Services...
WeissLaw LLP Investigates Juniper Pharmaceuticals, Inc. PR Newswire NEW YORK, July 5, 2018 NEW YORK, July 5, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty...
Juniper (JNP) Alert: Johnson Fistel Investigates Proposed Sale of Juniper Pharmaceuticals, Inc.; Are Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, July 3, 2018 SAN DIEGO, July 3, 2018...
Juniper Pharmaceuticals Signs Definitive Agreement to be Acquired by Catalent, Inc. for $11.50 Per Share in Cash PR Newswire BOSTON, July 3, 2018 BOSTON, July 3, 2018 /PRNewswire/ -- Juniper...
Juniper Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results Core Businesses Driving Strong Financial Performance CRINONE® Revenues Increased 30% and Juniper Pharma Services...
Juniper Pharmaceuticals to Report First Quarter 2018 Results on May 10, 2018 Conference Call Scheduled for 8:30 a.m. EST PR Newswire BOSTON, May 1, 2018 BOSTON, May 1, 2018 /PRNewswire/...
Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré Bioscience -Company Eligible to Receive Up to $43.75 Million in Milestones for Each IVR Candidate, Plus Royalties on...
Juniper Pharmaceuticals Appoints Richard Messina to Board of Directors PR Newswire BOSTON, March 21, 2018 BOSTON, March 21, 2018 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a...
Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results Full Year CRINONE® Revenues Increased 20% and Juniper Pharma Services (JPS) Revenues Increased 32...
Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2017 Results on March 8, 2018 Conference Call Scheduled for 8:30 a.m. EST PR Newswire BOSTON, March 2, 2018 BOSTON, March 2, 2018...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
